Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 2013



  Teva to Report Fourth Quarter and Full Year 2012 Financial Results on
  February 7, 2013

Business Wire

JERUSALEM -- January 22, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will
release its fourth quarter and full year 2012 financial results on Thursday,
February 7, 2013 at 7:00 a.m. EST.

Teva will host a conference call and live webcast on the same day, at 8:00
a.m. EST to discuss its fourth quarter and full year 2012 results and overall
business environment. A Question & Answer session will follow this discussion.

In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States and Canada
1-888-771-4371; International 1-847-585-4405; passcode: 34121499.

A live webcast of the call will also be available on Teva's website at:
www.tevapharm.com. Please log in at least 10 minutes prior to the conference
call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also be
accessed until February 14, 2013, at 11:59 p.m. ET by calling 1-888-843-7419
or 1-630-652-3042; passcode: 34121499#.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic drug
maker, with a global product portfolio of approximately 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $18.3 billion in net revenues in 2011.

Contact:

Teva
IR:
Kevin C. Mannix, 215-591-8912
United States
or
Joseph Marczely, 267-468-4281
United States
or
Tomer Amitai, 972 (3) 926-7656
Israel
or
PR:
Hadar Vismunski-Weinberg, 972 (3) 926-7687
Israel
or
Denise Bradley, 215-591-8974
United States
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement